UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials

Annals of oncology, 2015-09, Vol.26 (9), p.1808-1812

2015

Volltextzugriff (PDF)

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Annals of oncology, 2017-07, Vol.28 (7), p.1605-1611

2017

Volltextzugriff (PDF)

Phase I–II trial designs: how early should efficacy guide the dose recommendation process?

Annals of oncology, 2018-03, Vol.29 (3), p.540-541

2018

Volltextzugriff (PDF)

SP001 Biostatistical challenges for the design of biology-driven trials

European journal of cancer (1990), 2013-11, Vol.49, p.S1-S1

Paoletti, X

2013

Volltextzugriff (PDF)

Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program)

European heart journal, 2013-01, Vol.34 (2), p.112-120

2013

Volltextzugriff (PDF)

A comparison of model choices for the continual reassessment method in phase I cancer trials

Statistics in medicine, 2009-10, Vol.28 (24), p.3012-3028

2009

Volltextzugriff (PDF)

Designs of drug-combination phase I trials in oncology: a systematic review of the literature

Annals of oncology, 2015-04, Vol.26 (4), p.669-674

2015

Volltextzugriff (PDF)

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Annals of oncology, 2017-03, Vol.28 (3), p.590-596

2017

Volltextzugriff (PDF)

Designs of preoperative biomarkers trials in oncology: a systematic review of the literature

Annals of oncology, 2015-12, Vol.26 (12), p.2419-2428

2015

Volltextzugriff (PDF)

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

British journal of cancer, 2014-07, Vol.111 (1), p.17-24

2014

Volltextzugriff (PDF)

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

British journal of cancer, 2012-02, Vol.106 (5), p.854-857

2012

Volltextzugriff (PDF)

REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours

Annals of oncology, 2014-12, Vol.25 (12), p.2351-2356

2014

Volltextzugriff (PDF)

Consequences of running more operating theatres than anaesthetists to staff them: a stochastic simulation study

British journal of anaesthesia : BJA, 2007-04, Vol.98 (4), p.462-469

2007

Volltextzugriff (PDF)

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

Annals of oncology, 2019-02, Vol.30 Suppl 1, p.i5

2019

Volltextzugriff (PDF)

Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

ESMO open, 2022-02, Vol.7 (1), p.100366-100366, Article 100366

2022

Volltextzugriff (PDF)

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials

Annals of oncology, 2008-06, Vol.19 (6), p.1117-1126

2008

Volltextzugriff (PDF)

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens

ESMO open, 2023-08, Vol.8 (4), p.101616-101616, Article 101616

2023

Volltextzugriff (PDF)

Patients’ perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study

European journal of cancer care, 2017-11, Vol.26 (6), p.e12596-n/a

2017

Volltextzugriff (PDF)

Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study

Human reproduction (Oxford), 2004-10, Vol.19 (10), p.2216-2221

2004

Volltextzugriff (PDF)

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials

Annals of oncology, 2015-02, Vol.26 (2), p.422-428

2015

Volltextzugriff (PDF)

349 Impact of the re-definition of dose-limiting toxicities (DLTs) according to recent recommendations on the DLT rate in phase 1 trials of molecularly targeted agents

European journal of cancer (1990), 2015-09, Vol.51, p.S70-S70

2015

Volltextzugriff (PDF)

901 Reporting adverse events (AEs) in cancer surgery randomized trial: A systemic analysis of published trials in oesogastric (OG) and gynecological (GY) cancer patients

European journal of cancer (1990), 2015-09, Vol.51, p.S140-S140

2015

Volltextzugriff (PDF)

O3-1.2 How to perform a sensitivity analysis exploring the impact of missing not at random data with the R® software

Journal of epidemiology and community health (1979), 2011-08, Vol.65 (Suppl 1), p.A31-A31

2011

Volltextzugriff (PDF)

421 INVITED Tackling Futility With Adaptive Designs

European journal of cancer (1990), 2011, Vol.47, p.S92-S92

2011

Volltextzugriff (PDF)

A proposal for a new PhD level curriculum on quantitative methods for drug development

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2018-09, Vol.17 (5), p.593-606

2018

Volltextzugriff (PDF)

1 – 25 von 208

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(183)
Mit Volltextzugriff
(167)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Phase I–II trial designs: how early should efficacy guide the dose recommendation process?

SP001 Biostatistical challenges for the design of biology-driven trials

Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program)

A comparison of model choices for the continual reassessment method in phase I cancer trials

Designs of drug-combination phase I trials in oncology: a systematic review of the literature

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Designs of preoperative biomarkers trials in oncology: a systematic review of the literature

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours

Consequences of running more operating theatres than anaesthetists to staff them: a stochastic simulation study

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens

Patients’ perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study

Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials

349 Impact of the re-definition of dose-limiting toxicities (DLTs) according to recent recommendations on the DLT rate in phase 1 trials of molecularly targeted agents

901 Reporting adverse events (AEs) in cancer surgery randomized trial: A systemic analysis of published trials in oesogastric (OG) and gynecological (GY) cancer patients

O3-1.2 How to perform a sensitivity analysis exploring the impact of missing not at random data with the R® software

421 INVITED Tackling Futility With Adaptive Designs

A proposal for a new PhD level curriculum on quantitative methods for drug development

Suchergebnisse filtern